Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.

Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients with moderate-to-severe atopic dermatitis (AD); Describe the clinical profiles of targeted systemic therapies that are approved for pediatric patients with moderate-to-severe AD; and Outline patient-centered strategies to enhance long-term outcomes for pediatric patients with moderate-to-severe AD who are candidates for targeted systemic therapies.

Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand and foot dermatitis; and Outline future treatment considerations to optimize the use of novel systemic therapies in patients with moderate-to-severe atopic hand and foot dermatitis.

Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.

Please visit answersincme.com/MTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in eosinophilic gastrointestinal disease discusses the diagnosis and underlying pathophysiology targeted by potential treatments for eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Describe the burden associated with delayed detection and inadequate treatment of EoE; Identify strategies to provide timely diagnosis of EoE; and Recognize the therapeutic rationale for targeting type 2 inflammation factors to treat EoE.

Please visit answersincme.com/KVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the impact of emerging biologics on the treatment of moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for emerging biologic agents that target interleukin (IL)-13 cytokines for moderate-to-severe AD; and Outline how the latest data may inform the future use of emerging biologic agents that target IL-13 cytokines for moderate-to-severe AD within the context of the current treatment landscape.